If you have been reading about chelation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
| Property | Value | Notes |
|---|---|---|
| Physical state | Blue-violet solid | Typically supplied as lyophilized powder |
| Storage temperature | −20 °C or below | Desiccated, protected from light |
| Working stability | Hours to days at 2–8 °C | Depends on concentration and buffer |
| Identity test | RP-HPLC with UV-Vis | Visible absorbance near 600–630 nm |
| Copper assay | ICP-MS or AAS | Metal content confirms stoichiometry |
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
== NAAS selected bibliography == 1955 Nuclear magnetic resonance saturation and rotary saturation in solids. Physical Review 98(6):1787–1809. 1959 With A. G. Anderson. Nuclear spin-lattice relaxation in metals. Physical Review 116(3):583–591. 1963. Pure nuclear electric quadrupole resonance in impure copper. Physical Review 130(2):589–595. 1963 With M. Eisenstadt. Nuclear spin relaxation by translational diffusion in solids. Physical Review 132(2):635–643. Pure nuclear electric quadrupole resonance in impure copper. Physical Review 130(2):589–595. 1965 The theory of relaxation processes. In Advances in Magnetic and Optical Resonance, pp. 1–32. 1967 Local-field mapping in mixed-state superconducting vanadium by nuclear magnetic resonance. Physical Review 162(2):367–374. 1969 Nuclear spin thermodynamics in the rotating frame. Science 164(3883):1015–1023. 1970 With R. K. Gupta. Double nuclear magnetic resonance observation of electron exchange between ferri- and ferrocytochrome c. Science 169(3951):1204–1206. 1971 With H. E. Bleich. Higher resolution NMR of rare spins in solids [1]. The Journal of Chemical Physics 55(11):5405–5406. 1971 With R. K. Gupta. Pulsed Fourier transform nuclear magnetic resonance spectrometer. In Advances in Magnetic and Optical Resonance, pp. 81–115. 1973 With A. Z. Genack. Nuclear spin diffusion and its thermodynamic quenching in the field gradients of a Type-II superconductor. Physical Review Letters 31(19):1204–1207. 1975 With S. D. Kunz and E. K. Ralph. Dynamic range in Fourier transform proton magnetic resonance.
=== EC 1.6.6 With a nitrogenous group as acceptor === EC 1.6.6.1: Now EC 1.7.1.1, nitrate reductase (NADH) EC 1.6.6.2: Now EC 1.7.1.2, nitrate reductase [NAD(P)H] EC 1.6.6.3: Now EC 1.7.1.3, nitrate reductase (NADPH) EC 1.6.6.4: Now EC 1.7.1.4, nitrite reductase [NAD(P)H] EC 1.6.6.5: Now EC 1.7.2.1, nitrite reductase (NO-forming) EC 1.6.6.6: Now EC 1.7.1.5, hyponitrite reductase EC 1.6.6.7: Now EC 1.7.1.6, azobenzene reductase EC 1.6.6.8: Now EC 1.7.1.7, GMP reductase EC 1.6.6.9: Now known to be catalysed by EC 1.7.2.3, trimethylamine-N-oxide reductase EC 1.6.6.10: Now EC 1.7.1.9, nitroquinoline-N-oxide reductase] EC 1.6.6.11: Now EC 1.7.1.10, hydroxylamine reductase (NADH) EC 1.6.6.12: Now EC 1.7.1.11, 4-(dimethylamino)phenylazoxybenzene reductase EC 1.6.6.13: Now EC 1.7.1.12, N-hydroxy-2-acetamidofluorene reductase
It appears in the sex cord-stromal tumour group of ovarian neoplasms. Ovary fibromas are most frequent during middle age, and rare in children. Upon gross pathological inspection, ovary fibromas are firm and white or tan. Variants with edema are especially likely to be associated with Meigs' syndrome. On microscopic examination, there are intersecting bundles of spindle cells producing collagen. There may be thecomatous areas (fibrothecoma). The presence of an ovarian fibroma can cause ovarian torsion in some cases.
Instead, the ionic current from an action potential at one node of Ranvier provokes another action potential at the next node; this apparent "hopping" of the action potential from node to node is known as saltatory conduction. Although the mechanism of saltatory conduction was suggested in 1925 by Ralph Lillie, the first experimental evidence for saltatory conduction came from Ichiji Tasaki and Taiji Takeuchi and from Andrew Huxley and Robert Stämpfli. By contrast, in unmyelinated axons, the action potential provokes another in the membrane immediately adjacent, and moves continuously down the axon like a wave.
Sources: en.wikipedia.org
== Terminology structure == Each NPU entry holds a structured definition of the 'result type' it identifies. The definitions are expressed using well established concepts and terms from the field of laboratory medicine. References to internationally acknowledged classifications, nomenclatures and terminologies are filed where possible. This ensures that the definitions are unambiguous, and that the meaning of each concept will remain stable and accessible over time. The definition structure is based on the scientific concept of 'examination' – an examination studies one or more properties of a system (a delimited part of the universe). In a clinical laboratory terminology such as the NPU terminology the system of interest is assumed to be (part of) the patient or the environment, and the NPU definition structure states:
Some opioid antagonists are not pure antagonists because they produce weak opioid partial agonist effects, and can produce analgesic effects when administered in high doses to individuals who have never taken opioids. Examples of such compounds include nalorphine and levallorphan. However, the analgesic effects from these specific drugs are limited and tend to be accompanied by dysphoria, most likely due to additional agonist action at the κ-opioid receptor. As they induce opioid withdrawal effects in people who are taking, or have recently used, opioid full agonists, these drugs are generally considered to be antagonists for practical purposes. The weak partial agonist effect can be useful for some purposes, and has previously been used for purposes such as long-term maintenance of former opioid addicts using nalorphine, however it can also have disadvantages such as worsening respiratory depression in patients who have overdosed on non-opioid sedatives such as alcohol or barbiturates. On the other hand, Naloxone has no partial agonist effects, and is in fact a partial inverse agonist at μ-opioid receptors, and so is the preferred antidote drug for treating opioid overdose. Naloxone and naltrexone are commonly used opioid antagonist drugs which are competitive antagonists that bind to the opioid receptors with higher affinity than agonists but do not activate the receptors. This effectively blocks the receptor, preventing the body from responding to opioids and endorphins. Naloxone is a drug used to treat opioid overdose.
== External links == "Cipaglucosidase alfa with miglustat for treating Pompe disease [ID3771]". NICE. 12 July 2023. Clinical trial number NCT03729362 for "PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD" at ClinicalTrials.gov Clinical trial number NCT02675465 for "First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221" at ClinicalTrials.gov Clinical trial number NCT04138277 for "A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD" at ClinicalTrials.gov
Sources: en.wikipedia.org
=== Simple bond cleavage reactions === Majority of organic compounds undergo simple bond cleavage reactions, in which direct cleavage of bond take place. Sigma bond cleavage, radical site-initiated fragmentation, and charge site-initiated fragmentation are few types of simple bond cleavage reactions.
=== Passive systems === When combining a passive daytime radiative cooling system with thermal insulation and evaporative cooling, one study found a 300% increase in ambient cooling power when compared to a stand-alone radiative cooling surface, which could extend the shelf life of food by 40% in humid climates and 200% in desert climates without refrigeration. The system's evaporative cooling layer would require water "re-charges" every 10 days to a month in humid areas and every 4 days in hot and dry areas. A refrigeration system's coefficient of performance (CoP) is an important measure of its performance. It is defined as refrigeration capacity divided by the energy input required to operate the system. While CoP is a simple measure of performance, other measures such as performance factor (PF) are also used in some industrial refrigeration applications. A system's PF relates energy input to refrigeration capacity, and both CoP and PF depend on operating conditions, including temperatures and thermal loads.
Benefits of space exploration NASA STI Program, for NASA's Science and Technical Information program NASA Tech Briefs, for NASA innovations that are not necessarily commercial yet Timeline of United States inventions Timeline of United States discoveries National Inventors Hall of Fame Science and technology in the United States Technological and industrial history of the United States Space Foundation Space Certification Space Technology Hall of Fame
== Non-traditional use == In the late 20th century, the practice of ayahuasca drinking began spreading to Europe, North America and elsewhere. The first ayahuasca churches, affiliated with the Brazilian Santo Daime, were established in the Netherlands. A legal case was filed against two of the Church's leaders, Hans Bogers (one of the original founders of the Dutch Santo Daime community) and Geraldine Fijneman (the head of the Amsterdam Santo Daime community). Bogers and Fijneman were charged with distributing a controlled substance (DMT); however, the prosecution was unable to prove that the use of ayahuasca by members of the Santo Daime constituted a sufficient threat to public health and order such that it warranted denying their rights to religious freedom under ECHR Article 9. The 2001 verdict of the Amsterdam district court is an important precedent. Since then groups that are not affiliated to the Santo Daime have used ayahuasca, and a number of different "styles" have been developed, including non-religious approaches. In Peru, retreat centers such as Blue Morpho, founded by Hamilton Souther, in Iquitos began offering ayahuasca ceremonies to foreign visitors around 2004. International media coverage brought wider attention to the practice and coincided with the growth of ayahuasca tourism.
Sources: en.wikipedia.org
Dry powder is typically stored frozen at −20 °C or lower, protected from moisture and light. Short-term working amounts may be kept refrigerated. Avoiding repeated temperature changes helps preserve the material.
Reversed-phase HPLC with UV-visible detection is common because the copper complex absorbs visible light. Mass spectrometry provides molecular mass confirmation. Copper-specific methods such as ICP-MS quantify the metal content.
The blue color comes from copper-ligand interactions. Displacement of copper by chelators or changes in pH can shift or diminish the color. Such changes often indicate that the complex has been altered.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.